Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) compared with sorafenib Alone in patients with hepatocellular carcinoma (HCC) with major portal venous tumor thrombus (PVTT).
Hepatocellular Carcinoma
DRUG: Sorafenib|PROCEDURE: Hepatic arterial infusion chemotherapy|DRUG: Folfox Protocol
Overall survival, Overall survival, 6 months
Time to progression, Time to progression, 6 months|Adverse Events, Number of adverse events. Postoperative adverse events were graded based on CTCAE v3.0, 30 days|Number of of Patients developed Adverse Events, Number of of patients who developed adverse event. Postoperative adverse events were graded based on CTCAE v3.0, 30 days
The results of our preliminary pilot study suggested that sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) may improve the survivals for advanced stage HCC. Thus, the investigators carried out this prospective randomized control study to find out it.